Diabetes Management RACGP Exam: Clinical Guide & Questions

Diabetes mellitus is one of the most frequently tested clinical domains in both the RACGP Applied Knowledge Test (AKT) and Key Feature Problem (KFP) examinations. Because type 2 diabetes represents a massive chronic disease burden in Australian primary care, examiners consistently blueprint multiple questions targeting screening criteria, diagnostic thresholds, stepwise pharmacological titration, management of microvascular complications, and emergency presentations like diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS).

Many candidates lose marks in this domain due to unfamiliarity with recent Australian guideline updates, particularly regarding the role of SGLT2 inhibitors and GLP-1 receptor agonists in patients with established cardiovascular disease, chronic kidney disease (CKD), or heart failure. Furthermore, candidates often fail to demonstrate appropriate marking discipline in KFP answers when outlining microvascular monitoring schedules or selecting HbA1c targets.

This clinical revision guide provides a comprehensive breakdown of high-yield diabetes presentations, maps them directly to current Therapeutic Guidelines and the RACGP Red Book, and highlights the examiner-reported errors you must avoid to secure passing marks.

The Diagnostic Thresholds: Clear Criteria

A common error on the AKT is misinterpreting borderline glycemic results or initiating pharmacological therapy prematurely without a confirmed diagnosis. You must memorize the precise diagnostic criteria for diabetes in Australia:

Asymptomatic Patients

For patients without symptoms of hyperglycaemia, a diagnosis of diabetes must never be made based on a single abnormal test. Diagnosis requires two abnormal results on separate days from any of the following parameters:

• HbA1c: 6.5% (48 mmol/mol) or greater.
• Fasting Venous Plasma Glucose: 7.0 mmol/L or greater (fasting is defined as no caloric intake for at least 8 hours).
• Random Venous Plasma Glucose: 11.1 mmol/L or greater.
• 2-hour Oral Glucose Tolerance Test (OGTT): 11.1 mmol/L or greater (following a 75g oral glucose load).

If a patient has two different tests performed (e.g. HbA1c and fasting glucose) and both are above the diagnostic threshold, this confirms the diagnosis. If the results are discordant, the test that is above the threshold should be repeated, and the diagnosis is confirmed if the repeat test is abnormal.

Symptomatic Patients

For patients presenting with classic symptoms of hyperglycaemia (polyuria, polydipsia, unexplained weight loss, lethargy, or recurrent infections), a diagnosis can be confirmed with a single abnormal venous plasma glucose result (fasting of 7.0 mmol/L or greater, or random of 11.1 mmol/L or greater) or a single HbA1c of 6.5% or greater.

Impaired Glucose Tolerance vs Impaired Fasting Glucose

You must be able to distinguish between pre-diabetic states on the AKT:

• Impaired Fasting Glucose (IFG): Fasting venous plasma glucose between 6.1 mmol/L and 6.9 mmol/L, with a 2-hour OGTT of less than 7.8 mmol/L.
• Impaired Glucose Tolerance (IGT): Fasting venous plasma glucose of less than 7.0 mmol/L, with a 2-hour OGTT between 7.8 mmol/L and 11.0 mmol/L.

Screening Guidelines: Red Book Standards

Screening for type 2 diabetes in asymptomatic, average-risk individuals is highly tested, particularly in clinical scenario questions where you must determine the appropriate age to start screening or select the correct screening tool.

In alignment with the RACGP Red Book (Guidelines for preventive activities in general practice), screening recommendations are structured as follows:

General Population

• Tool: Use the Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) score.
• Starting Age: Start screening at age 40 years.
• Frequency: Re-assess using the AUSDRISK score every 3 years.
• Diagnostic Action: For patients with an AUSDRISK score of 12 or greater (indicating high risk), perform a fasting venous plasma glucose or an HbA1c test.

First Nations People

• Starting Age: Start screening at age 18 years.
• Frequency: Perform blood testing (fasting glucose or HbA1c) every 3 years. The AUSDRISK tool is not required for First Nations people as they are automatically classified as high risk due to epidemiological prevalence.

Pharmacological Management: Stepwise Titration

Therapeutic Guidelines detail a strict, structured hierarchy for the pharmacological management of type 2 diabetes. AKT and KFP questions test your ability to navigate this hierarchy, select appropriate combination therapies, and recognise contraindications.

First-Line Therapy: Metformin

Unless contraindicated, metformin remains the first-line pharmacological agent for all patients with type 2 diabetes:

• Starting Dose: Start at a low dose (e.g. 500mg daily or twice daily with meals) to minimise gastrointestinal side effects (nausea, abdominal bloating, diarrhoea).
• Titration: Slowly titrate the dose over several weeks to a target maintenance dose of 2g daily (1g twice daily).
• Renal Adjustment: Monitor renal function closely. If the eGFR falls between 30 mL/min/1.73m2 and 45 mL/min/1.73m2, reduce the maximum dose to 1g daily. Metformin is strictly contraindicated if the eGFR falls below 30 mL/min/1.73m2 due to the risk of lactic acidosis.

Selecting Second-Line Therapy: The Clinical Split

When the target HbA1c is not achieved on a maximum tolerated dose of metformin, the selection of the second-line agent is determined by the patient's underlying comorbidities rather than glycemic levels alone. This is a critical AKT topic:

1. Established Cardiovascular Disease, Chronic Kidney Disease, or Heart Failure

For patients with established atherosclerotic cardiovascular disease, heart failure (specifically HFrEF), or chronic kidney disease (eGFR between 20 mL/min/1.73m2 and 60 mL/min/1.73m2, or macroalbuminuria), you must choose an agent with proven cardiorenal protection as the second-line add-on:

• SGLT2 Inhibitor (e.g. dapagliflozin, empagliflozin): Preferred in patients with heart failure or significant chronic kidney disease. They promote urinary glucose excretion and carry significant osmotic benefits. SGLT2 inhibitors carry a risk of euglycaemic diabetic ketoacidosis (DKA), genitourinary tract infections, and must be suspended 2-3 days prior to major surgery or during acute illness ("sick day" protocol).
• GLP-1 Receptor Agonist (e.g. semaglutide, dulaglutide): Preferred in patients with established cardiovascular disease where weight loss is a key clinical goal, or where SGLT2 inhibitors are contraindicated or poorly tolerated. Administered via subcutaneous injection. GLP-1 RAs delay gastric emptying and are contraindicated in patients with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN 2).

2. Uncomplicated Diabetes (No Cardiorenal Comorbidities)

For patients without established cardiovascular disease, renal impairment, or heart failure, the second-line agent can be selected from any of the following classes based on patient preference, weight goals, tolerability, and PBS criteria:

• DPP-4 Inhibitors (e.g. sitagliptin, linagliptin): Weight-neutral, low risk of hypoglycaemia, well-tolerated. Linagliptin is highly useful in renal impairment as it does not require dose adjustment. DPP-4 inhibitors must never be combined with GLP-1 receptor agonists as they share the same incretin pathway.
• SGLT2 Inhibitors: Indicated if weight loss is desired or to avoid hypoglycaemia.
• GLP-1 Receptor Agonists: High glycemic efficacy and significant weight loss benefit.
• Sulfonylureas (e.g. gliclazide): High glycemic efficacy but carry a significant risk of hypoglycaemia and weight gain. Low cost makes them useful when access is limited.

Target HbA1c: Individualised Care

Choosing the correct target HbA1c is a high-yield clinical decision point. Examiners consistently test your ability to individualise glycemic targets based on patient demographics, duration of disease, and cardiovascular risk.

• General Target (7.0% or less): This is the standard target for most adults with type 2 diabetes. It is sufficient to reduce the long-term risk of microvascular complications without exposing the patient to excessive hypoglycaemic risk.
• Tight Target (6.5% or less): Consider a tighter target in patients who have a short duration of diabetes, long life expectancy, no established cardiovascular disease, and are managed with lifestyle modifications or metformin alone.
• Relaxed Target (7.5% to 8.0%): You must select a relaxed glycemic target for patients with a history of severe hypoglycaemia, limited life expectancy, severe microvascular or macrovascular complications, multiple co-morbidities, or long-standing diabetes.

Microvascular Complications: Annual Monitoring Schedules

Marking grids in the KFP are highly specific when assessing your knowledge of microvascular screening schedules. You must learn the exact parameters and intervals required for comprehensive diabetes management.

Diabetic Kidney Disease (Nephropathy)

Screening must occur annually from the time of diagnosis of type 2 diabetes:

• Urinary Albumin-to-Creatinine Ratio (UACR): A spot urine sample. Microalbuminuria is defined as 2.5-25 mg/mmol in men and 3.5-35 mg/mmol in women.
• Estimated Glomerular Filtration Rate (eGFR): Checked via serum creatinine.
• Management: If microalbuminuria is confirmed on at least two separate samples over a 3-month period, initiate an ACE inhibitor or an ARB at the maximum tolerated dose, even if the patient is normotensive, to provide renal protection. Add an SGLT2 inhibitor if eGFR is greater than 20 mL/min/1.73m2.

Diabetic Retinopathy

Screening intervals are determined by underlying risk and previous findings:

• No Retinopathy (General): Dilated eye examination or retinal photography every 2 years.
• No Retinopathy (First Nations): Screen annually due to a higher risk of rapid disease progression.
• Established Retinopathy: Screen annually or more frequently as directed by an ophthalmologist or optometrist.

Diabetic Neuropathy and Foot Care

Assess the patient's feet at least annually (more frequently if high risk):

• Neurological assessment: 10g monofilament test at 4-10 standardized sites per foot, combined with assessment of vibration sensation (using a 128Hz tuning fork) and ankle reflexes.
• Vascular assessment: Palpate dorsalis pedis and posterior tibial pulses. Measure ankle-brachial index (ABI) if pulses are reduced.
• Visual inspection: Screen for dry skin, tinea pedis, structural deformities (Charcot joint, claw toes), calluses, or active ulceration.

Top 5 Examiner-Reported Diabetes Errors

Official RACGP public exam reports highlight specific recurring mistakes that candidates make in diabetes questions. Reviewing these errors will prevent you from losing straightforward marks.

1. 1
   Combining DPP-4 Inhibitors and GLP-1 Receptor Agonists

   Candidates frequently select both sitagliptin and semaglutide in combination therapeutic management plans. This is a pharmacological error. Both classes target the incretin pathway. Co-prescribing provides no additional glycemic benefit and significantly increases gastrointestinal side effects.

2. 2
   Prescribing Metformin in Severe Renal Impairment (eGFR < 30)

   Under exam pressure, candidates often fail to review the baseline eGFR before selecting metformin or increasing its dose. Prescribing metformin to a patient with an eGFR less than 30 mL/min/1.73m2 is a severe clinical error due to the high risk of lactic acidosis. Always cease metformin entirely if eGFR falls below 30.

3. 3
   Neglecting the SGLT2 Inhibitor "Perioperative Sick Day" Protocol

   In surgical scenario questions, candidates often fail to instruct patients to suspend SGLT2 inhibitors prior to elective procedures. SGLT2 inhibitors must be suspended 2-3 days before major elective surgeries or during periods of acute severe illness (dehydration, severe infections) to prevent euglycaemic DKA.

4. 4
   Initiating Pharmacological Therapy Based on a Single Asymptomatic Result

   Candidates often select immediate initiation of metformin for an asymptomatic patient presenting with a single fasting glucose of 7.2 mmol/L. For asymptomatic patients, a diagnosis of diabetes must never be made on a single test. The correct next step is to repeat the fasting glucose or perform an HbA1c to confirm the diagnosis before starting treatment.

5. 5
   Selecting an Inappropriately Tight HbA1c Target in Frail Older Patients

   Candidates frequently apply a rigid HbA1c target of <= 6.5% or <= 7.0% to an 82-year-old patient with established cognitive impairment and multiple falls. This is clinically unsafe. The risk of severe hypoglycaemia in frail older adults outweighs the microvascular benefits of tight control. A relaxed target of 7.5% to 8.0% is the correct clinical choice.

Frequently Asked Questions